首页> 外文期刊>Oncology letters >First application of next-generation sequencing in Moroccan breast/ovarian cancer families and report of a novel frameshift mutation of the BRCA1 gene
【24h】

First application of next-generation sequencing in Moroccan breast/ovarian cancer families and report of a novel frameshift mutation of the BRCA1 gene

机译:下一代测序在摩洛哥乳腺癌/卵巢癌家族中的首次应用,以及BRCA1基因的新型移码突变的报道

获取原文
获取原文并翻译 | 示例
           

摘要

At present, breast cancer is the most common type of cancer in females. The majority of cases are sporadic, but 5-10% are due to an inherited predisposition to develop breast and ovarian cancers, which are transmitted as an autosomal dominant form with incomplete penetrance. The beneficial effects of clinical genetic testing, including next generation sequencing (NGS) for BRCA1/2 mutations, is major; in particular, it benefits the care of patients and the counseling of relatives that are at risk of breast cancer, in order to reduce breast cancer mortality. BRCA genetic testing was performed in 15 patients with breast cancer and a family with positivity for the heterozygous c.6428C>A mutation of the BRCA2 gene. Informed consent was obtained from all the subjects. Genomic DNAs were extracted and the NGS for genes was performed using the Ion Torrent Personal Genome Machine (PGM) with a 316 chip. The reads were aligned with the human reference HG19 genome to elucidate variants in the BRCA1 and BRCA2 genes. Mutations detected by the PGM platform were confirmed by target direct Sanger sequencing on a second patient DNA sample. In total, 4 BRCA variants were identified in 6 families by NGS. Of these, 3 mutations had been previously reported: c.2126insA of BRCA1, and c.1310_1313delAAGA and c.7235insG of BRCA2. The fourth variant, c.3453delT in BRCA1, has, to the best of our knowledge, never been previously reported. The present study is the first to apply NGS of the BRCA1 and BRCA2 genes to a Moroccan population, prompting additional investigation into local founder mutations and variant characteristics in the region. The variants with no clear clinical significance may present a diagnostic challenge when performing targeted resequencing. These results confirm that an NGS approach based on Ampliseq libraries and PGM sequencing is a highly efficient, speedy and high-throughput mutation detection method, which may be preferable in lower income countries.
机译:当前,乳腺癌是女性中最常见的癌症类型。大多数病例为偶发性,但5-10%是由于遗传易感性发展为乳腺癌和卵巢癌,它们以常染色体显性形式传播,且渗透率不完全。临床遗传测试的有益作用是主要的,包括用于BRCA1 / 2突变的下一代测序(NGS)。特别是,它有利于照顾有患乳腺癌风险的患者并向亲属提供咨询,以降低乳腺癌的死亡率。在15例乳腺癌患者和一个对BRCA2基因的杂合c.6428C> A突变呈阳性的家庭中进行了BRCA基因测试。从所有受试者获得知情同意。提取基因组DNA,并使用带有316芯片的离子激流个人基因组机(PGM)进行基因的NGS。将读数与人类参考HG19基因组进行比对,以阐明BRCA1和BRCA2基因的变异体。通过PGM平台检测到的突变已通过在第二例患者DNA样品上进行靶标直接Sanger测序证实。 NGS共在6个家族中鉴定出4种BRCA变体。其中,先前已经报道了3个突变:BRCA1的c.2126insA和BRCA2的c.1310_1313delAAGA和c.7235insG。据我们所知,第四种变体,BRCA1中的c.3453delT,以前从未被报道过。本研究是第一个将BRCA1和BRCA2基因的NGS应用于摩洛哥人群的方法,这促使对该区域的本地创始人突变和变异特征进行进一步研究。当进行靶向重测序时,没有明确临床意义的变体可能会提出诊断挑战。这些结果证实,基于Ampliseq文库和PGM测序的NGS方法是一种高效,快速且高通量的突变检测方法,在低收入国家中可能更可取。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号